Stoke Therapeutics
STOK
99 hedge funds and large institutions have $871M invested in Stoke Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 15 closing their positions.
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
14.36% more ownership
Funds ownership: 96.33% → 110.69% (+14%)
5% more funds holding
Funds holding: 94 → 99 (+5)
2% more capital invested
Capital invested by funds: $855M → $871M (+$16M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$48.6M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$26.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.8M |
| 4 |
CAC
Cowen and Company
New York
|
+$22.5M |
| 5 |
Millennium Management
New York
|
+$5.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.3M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$10.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.61M |
| 4 |
WWM
Westwood Wealth Management
Los Angeles,
California
|
-$5.28M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$4.45M |
STOK Hedge Fund Activity: Q1 2022 in Review
99 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2022, worth a combined $871M — up 1.9% from $855M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STOK positions and 15 closed out — a net gain of 5 holders — while 36 added to existing stakes and 27 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $48.6M. The largest seller was Federated Hermes, cutting an estimated $13.3M.
- 99 institutional investors held Stoke Therapeutics (STOK) as of Q1 2022, up from 94 in Q4 2021.
- Funds reported $871M of Stoke Therapeutics stock for Q1 2022, up 1.9% quarter-over-quarter.
- 20 funds opened new Stoke Therapeutics positions in Q1 2022 and 15 closed out, a net change of +5 holders.
- The largest Stoke Therapeutics buyer in Q1 2022 was Morgan Stanley, an estimated $48.6M added.
- The largest Stoke Therapeutics seller in Q1 2022 was Federated Hermes, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2022.